GlassScriptPhysician profile
Heather A Larsen
NPI 1487021358
$9,111.15
in general payments reported to CMS, 2019-2025
29 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,430 · 2022: $1,768 · 2023: $1,750 · 2024: $2,013 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,897 · Education: $15.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,896.95 |
| Education | $15.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,809.81 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $856.48 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $739.23 | 2021-2025 | Entyvio, Eohilia, Fosrenol |
| Janssen Biotech, INC. | $667.18 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $511.56 | 2021-2025 | Linzess |
| Phathom Pharmaceuticals, INC. | $308.52 | 2024-2025 | Voquezna |
| Genzyme Corporation | $297.46 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $295.06 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $282.66 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Pfizer INC. | $280.48 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $276.07 | 2023-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $252.10 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $248.30 | 2021-2024 | Dificid |
| Madrigal Pharmaceuticals | $200.63 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $174.37 | 2021-2023 | Ocaliva |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $157.08 | 2022-2025 | Ibsrela |
| Celgene Corporation | $144.75 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $138.50 | 2023-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $74.02 | 2021-2023 | Cimzia |
| Novo Nordisk INC | $59.26 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $56.93 | 2024-2025 | Iqirvo, Bylvay |
| Celltrion USA INC. | $55.53 | 2024-2025 | Vegzelma, Zymfentra |
| Amgen INC. | $50.48 | 2022-2023 | Amjevita |
| Qol Medical, LLC | $45.78 | 2021-2022 | |
| Sandoz INC. | $35.94 | 2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.89 | 2023 | Cyltezo |
| Micro-Tech Endoscopy USA, INC. | $25.48 | 2022-2023 | Dat Closure Device |
| Daiichi Sankyo INC. | $24.00 | 2022 | |
| Gilead Sciences, INC. | $15.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Larsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.